Special Issue "Nutrition Therapy for Diarrhea in Cancer Patients"

A special issue of Nutrients (ISSN 2072-6643). This special issue belongs to the section "Clinical Nutrition".

Deadline for manuscript submissions: 31 August 2021.

Special Issue Editors

Dr. Salvatore Artale
Website
Guest Editor
Oncology Departement, Ospedale di Gallarate, ASST Valle Olona, Gallarate, Italy
Interests: neuroendocrine tumours; colorectal cancer; nutrition; vitamin deficiencies; vitamin D deficiency ; niacin; fat-soluble vitamins; malnutrition; chemotherapy-induced diarrhea ; dietary habits; food intolerance; lifestyle; mediterranean diet
Dr. Riccardo Caccialanza
Website
Guest Editor
Clinical Nutrition and Dietetics Unit, IRCCS Policlinico San Matteo Foundation, 27100 Pavia, Italy
Interests: Nutrition; Metabolism; Nutrition Assessment; Clinical Nutrition; Malnutrition Nutritional Medicine; Dietetics; Nutritional Status; Nutritional Biochemistry; Nutritional Requirements; Nutrition Performance
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

As you know, diarrhea is a severe and common problem among cancer patients both during and after treatment for the disease, which may lead to treatment interruptions and even discontinuation. The main cause of chronic diarrhea is represented by cytotoxic agents, but targeted drugs, radiotherapy and immunotherapy can also cause this condition. Treatment-induced diarrhea can be severe and be associated with malnutrition, dehydration and electrolyte abnormalities with significant impact on quality of life and social functioning. Given the significant clinical impact of malnutrition on cancer patients, nutritional therapy should be an integral part of cancer treatment as a supportive measure. This support can lead to an improvement in the nutritional status and suppression of the gluconeogenesis associated with cancer cachexia. Nutritional support has also been shown to positively impact clinical outcomes, including improvement in tolerance to therapy, reduced hospitalizations, reduction in operative morbidity and mortality and improved sense of well-being.

In this Special Issue of Nutrients, we would like to invite experts to contribute with original research or review articles that investigate :

  • the role of nutritional therapy in the management of diarrhea in cancer patients;
  • the impact of cancer and its treatment on nutritional factors with emphasis on malnutrition, dietary approaches and quality of life.
Dr. Salvatore Artale
Dr. Riccardo Caccialanza
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nutrients is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Cancer
  • Chemotherapy
  • Radiotherapy
  • Immunotherapy
  • Toxicity
  • Malnutrition
  • Diarrhea
  • Nutrition
  • Vitamin D
  • Intestinal microbiota
  • Probiotics

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
Lactobacillus Kefiri LKF01 (Kefibios®) for Prevention of Diarrhoea in Cancer Patients Treated with Chemotherapy: A Prospective Study
Nutrients 2021, 13(2), 385; https://doi.org/10.3390/nu13020385 - 27 Jan 2021
Abstract
Diarrhoea is one of the main side effects that cancer patients face. The literature showsthat the incidence of chemotherapy (CT)-induced diarrhoea (grade 3–4) in treated patients is in the range of 10–20%, particularly after 5-fluorouracil (5-FU) bolus or some combination therapies of irinotecan [...] Read more.
Diarrhoea is one of the main side effects that cancer patients face. The literature showsthat the incidence of chemotherapy (CT)-induced diarrhoea (grade 3–4) in treated patients is in the range of 10–20%, particularly after 5-fluorouracil (5-FU) bolus or some combination therapies of irinotecan and fluoropyrimidines. The aim of the present study was to evaluate the clinical effectiveness of Lactobacillus kefiri LKF01 (Kefibios®) in the prevention or treatment of CT-related diarrhoea in the cancer population. We conducted a prospective observational study. Patients enrolled were adults treated for at least four months with 5-FU-based CT. Kefibios® was administered to patients every day. The primary outcome was the evaluation of the incidence of grade 3–4 CT-induced diarrhoea. We included 76 patients in the final analysis. A 6.6% incidence of high-grade diarrhoea was found in the evaluated population (4.7% of patients treated with 5-FU-based therapy and 8.5% of patients treated with capecitabine-based CT). The overall incidence of high-grade diarrhoea observed was higher in the 1st and 2nd cycles (3.9%), with a subsequent sharp reduction from the 3rd cycle (1.3%) and negativisation from the 5th cycle. Lactobacillus kefiri LKF01 (Kefibios®) is safe and effective in preventing severe diarrhoea in cancer patients receiving 5-FU or capecitabine-based treatment. Full article
(This article belongs to the Special Issue Nutrition Therapy for Diarrhea in Cancer Patients)
Show Figures

Figure 1

Back to TopTop